UBS analyst Trung Huynh raised Regeneron Pharmaceuticals, Inc. (REGN) price target to $584 from $560, maintaining a Neutral rating before the second-quarter earnings report. The move reflects optimism for the company’s financial performance, driven by the strength of flagship eye treatment, Eylea, amid competition in the ophthalmology space.

Despite the positive revision, UBS remains cautious on REGN due to a balance of risks and rewards. The firm notes that the stock’s current price already reflects near-term optimism, with limited room for upside unless new catalysts emerge. The upcoming earnings release may provide insight for momentum going forward.

While acknowledging REGN’s potential, UBS suggests other AI stocks may offer greater upside with less downside risk. For those seeking undervalued AI stocks, a free report is available on the best short-term AI stock. The article also mentions top healthcare AI stocks and consumer defensive stocks.

Read more at Yahoo Finance: UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating